Carina Dinkel-Keuthage is a Real World Evidence (RWE) Researcher at Bayer, specializing in the planning, execution, and interpretation of RWE studies across all phases of product development. With expertise in both prospective and retrospective observational research, she plays a key role in generating insights that inform clinical and regulatory decision-making. As the business owner for OHDSI and the OMOP Common Data Model at Bayer, Carina also drives the integration and standardization of real-world data to enhance the quality and consistency of evidence generation.

Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. We design our products and services to serve the most essential human needs of health and nutrition. At the same time, we strive to address some of the world’s biggest challenges presented by a growing and aging global population. At Bayer, we’re committed to driving sustainable development and generate a positive impact with our businesses. Through the power of science, we’re pioneering new possibilities that advance life for all of us. That means reimagining how we care for ourselves and one another by empowering everyday health, improving approaches to patient care, and finding better ways to nourish our communities around the world.